An acquired HER2T798I “gatekeeper” mutation, homologous to the EGFRT790M mutation in EGFR inhibitor-resistant lung cancer (Table 2), was recently identified in a HER2-mutant breast cancer patient following progression on neratinib [91]. This evidence concerns the gene ERBB2 and breast carcinoma.